Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Enanta Pharmaceuticals, Inc. ENTA

Healthcare  —  Biotechnology
11.88 (0.12) (1.00%) as of 25 Sep
Market cap
$349.5M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Enanta Pharmaceuticals, Inc. (ENTA) Business Profile

Updated before January 2025

Company Overview

Enanta Pharmaceuticals, Inc. (ENTA) is a biotechnology company specializing in the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Founded in 1995 and headquartered in Watertown, Massachusetts, Enanta has established itself as a leader in the pharmaceutical industry by focusing on innovative therapies for unmet medical needs. The company was co-founded by Dr. Peter Mueller, a renowned scientist with extensive experience in drug discovery and development. Enanta’s leadership team includes President and CEO Jay R. Luly, Ph.D., who has been instrumental in driving the company’s strategic vision and growth. Under his leadership, Enanta has achieved significant milestones in drug discovery and clinical development.

Core Business Segments

Enanta Pharmaceuticals operates primarily in the following core business segments:

1. Hepatitis C Virus (HCV) Therapies

Enanta has developed a portfolio of small molecule inhibitors targeting the Hepatitis C virus. Its key contribution to this segment is its collaboration with AbbVie, which led to the development of glecaprevir, a protease inhibitor used in combination therapies for HCV treatment. Glecaprevir is a component of Mavyret®, a leading HCV therapy.

2. Respiratory Syncytial Virus (RSV) Therapies

Enanta is actively developing therapies for RSV, a common respiratory virus that can cause severe infections in infants, older adults, and immunocompromised individuals. The company’s lead RSV candidate, EDP-938, is a potent N-protein inhibitor currently in clinical trials.

3. Hepatitis B Virus (HBV) Therapies

Enanta is advancing its pipeline of therapies for chronic Hepatitis B, a significant global health challenge. The company’s HBV program focuses on developing small molecule inhibitors targeting various aspects of the HBV lifecycle, including capsid assembly and viral replication.

4. Non-Alcoholic Steatohepatitis (NASH) Therapies

Enanta is also exploring treatments for NASH, a progressive liver disease associated with fat accumulation, inflammation, and fibrosis. The company’s lead candidate in this segment, EDP-305, is a Farnesoid X Receptor (FXR) agonist designed to address the underlying causes of NASH.

Business Model

Enanta Pharmaceuticals operates on a hybrid business model that combines internal drug discovery and development with strategic partnerships. The company generates revenue through:

  • Collaborations and Licensing Agreements: Enanta collaborates with major pharmaceutical companies like AbbVie to develop and commercialize its drug candidates. These partnerships provide upfront payments, milestone payments, and royalties on product sales.
  • Proprietary Drug Development: Enanta invests heavily in its proprietary pipeline, focusing on high-value therapeutic areas such as viral infections and liver diseases. By advancing its candidates through clinical trials, the company aims to bring innovative therapies to market and capture significant market share.

Strategic Direction

Enanta Pharmaceuticals is committed to expanding its portfolio of innovative therapies and addressing unmet medical needs. The company’s strategic priorities include:

  • Pipeline Expansion: Enanta is focused on advancing its clinical-stage candidates, including EDP-938 for RSV, EDP-514 for HBV, and EDP-305 for NASH. The company is also exploring new therapeutic areas and targets.
  • Global Market Penetration: Enanta aims to expand its presence in international markets by collaborating with global pharmaceutical companies and pursuing regulatory approvals in key regions.
  • Sustainability Goals: Enanta is dedicated to conducting its operations responsibly and minimizing its environmental impact. The company integrates sustainability practices into its research, development, and manufacturing processes.

Competitive Landscape

Enanta Pharmaceuticals operates in a highly competitive industry, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Gilead Sciences: A leader in antiviral therapies, Gilead competes with Enanta in the HCV and HBV markets.
  • Bristol-Myers Squibb: Another major player in the antiviral space, Bristol-Myers Squibb develops therapies for HBV and other viral infections.
  • Intercept Pharmaceuticals: A competitor in the NASH segment, Intercept focuses on FXR agonists and other liver disease therapies.
  • Vir Biotechnology: An emerging biotech company specializing in infectious disease therapies, Vir competes with Enanta in the RSV and HBV markets.

Risk Factors

Enanta Pharmaceuticals faces several risks that could impact its business operations and financial performance:

  • Market Dependence: Enanta relies heavily on its collaboration with AbbVie for revenue generation. Any changes in this partnership could significantly affect the company’s financial stability.
  • Clinical and Regulatory Risks: The success of Enanta’s pipeline depends on the outcomes of clinical trials and regulatory approvals, which are inherently uncertain and time-consuming.
  • Supply Chain Disruptions: The company’s operations could be affected by disruptions in the supply chain, including shortages of raw materials and manufacturing delays.
  • Competition: Intense competition in the pharmaceutical industry could limit Enanta’s market share and pricing power.

Recent Developments

Enanta Pharmaceuticals has made significant progress in its research and development efforts. Recent developments include:

  • Advancement of EDP-938: Enanta has initiated Phase 2 clinical trials for EDP-938, its lead RSV candidate, demonstrating promising antiviral activity and safety profiles.
  • Expansion of HBV Program: The company has advanced EDP-514, a novel core inhibitor for HBV, into clinical trials, aiming to address the unmet needs of chronic HBV patients.
  • Collaboration with AbbVie: Enanta continues to benefit from its partnership with AbbVie, with Mavyret® maintaining a strong position in the HCV market.
  • COVID-19 Research: Enanta has initiated preclinical studies to evaluate potential therapies for COVID-19, leveraging its expertise in antiviral drug discovery.

Investment Considerations

Investors considering Enanta Pharmaceuticals should weigh the following strengths and risks:

Strengths

  • Strong Pipeline: Enanta has a robust pipeline of clinical-stage candidates targeting high-value therapeutic areas.
  • Strategic Partnerships: The company’s collaboration with AbbVie provides a stable revenue stream and access to global markets.
  • Innovative R&D: Enanta’s focus on small molecule drug discovery positions it as a leader in antiviral and liver disease therapies.

Risks

  • Revenue Concentration: Dependence on AbbVie for a significant portion of revenue poses a risk to financial stability.
  • Clinical and Regulatory Uncertainty: The success of Enanta’s pipeline depends on the outcomes of clinical trials and regulatory approvals.
  • Market Competition: Intense competition from established pharmaceutical companies and emerging biotech firms could impact Enanta’s market share.

Conclusion

Enanta Pharmaceuticals, Inc. is a leading biotechnology company with a strong focus on antiviral and liver disease therapies. With a robust pipeline, strategic partnerships, and a commitment to innovation, Enanta is well-positioned to address unmet medical needs and drive future growth. However, the company faces challenges such as revenue concentration, clinical and regulatory risks, and market competition. Overall, Enanta represents a compelling investment opportunity for those seeking exposure to the biotechnology sector, particularly in the areas of viral infections and liver diseases.